In the drug evaluation “Efficacy and safety of intranasal xylometazoline and ipratropium in patients with common cold” by Graf P et al. published in the April 2009 issue of Expert Opinion on Pharmacotherapy (Expert Opin. Pharmacother. (2009) 10(5):889-908), there should have been a declaration of interest statement on page 906 disclosing the following:
Novartis sponsored the medical writing of this paper and S Chen is an employee of Novartis.
In the drug evaluation “Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs”, by Silasi D-A et al., published in the April 2009 issue of Expert Opinion on Pharmacotherapy (Expert Opin. Pharmacother. (2009) 10(6):1059-1067), the declaration of interest on page 1066 should have read as follows:
David Brown is employed by Marshall Edwards Pty Ltd, a subsidiary of Novogen (the manufacturers of Phenoxodiol).
The authors and publisher sincerely regret any inconvenience that these omissions may have caused.